(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 April 2012 (19.04.2012)

PCT

(10) International Publication Number
WO 2012/050695 A1

(51) **International Patent Classification**:
A61K 38/46 (2006.01) ***A61K 31/135*** (2006.01)
A61K 31/366 (2006.01) ***A61P 3/06*** (2006.01)
A61K 31/397 (2006.01)

(21) **International Application Number**:
PCT/US2011/051096

(22) **International Filing Date**:
9 September 2011 (09.09.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/403,011 9 September 2010 (09.09.2010) US
61/456,014 29 October 2010 (29.10.2010) US
61/432,372 13 January 2011 (13.01.2011) US
PCT/US2011/033699 23 April 2011 (23.04.2011) US

(71) **Applicant** *(for all designated States except US)*: **SYNAGEVA BIOPHARMA CORP.** [US/US]; 128 Spring Street, Suite 520, Lexington, Massachusetts 02421 (US).

(72) **Inventor; and**
(75) **Inventor/Applicant** *(for US only)*: **QUINN, Anthony** [GB/US]; 107 Manet Road, Chestnut Hill, Massachusetts 02467 (US).

(74) **Agents**: **HAANES, Elizabeth** et al.; Sterne Kessler Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, DC 20005 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/050695 A1

(54) **Title**: USE OF LYSOSOMAL ACID LIPASE FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS

(57) **Abstract**: The present invention provides treating LAL deficiency (e.g. Wolman's disease, CESD) comprising administering to a mammal a therapeutically effective amount o lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided